The Federal Reserve could have reason to 'dial back' from its 75-basis-point interest rate hikes if new data shows inflation "clearly" slowing, Atlanta Fed President Raphael Bostic said in an essay published on Tuesday.
Facebook Joins Meta’s Instagram in Supporting NFTs
Users can now link their crypto wallets and begin sharing their digital collectibles, parent company Meta Platforms said.
Expect Apple to show four new iPhones and an updated Apple Watch next week
Apple is holding a launch event at its headquarters in Cupertino, California, on Sept. 7. The company is expected to announce new iPhone models, as it has every September since 2012.
Honda, LG Set to Build $4.4 Billion EV Battery Plant in US
The duo’s joint venture is for a 40GWh EV battery plant Location of the facility in the US is not yet decided
Amazon signs green hydrogen supply deal with Plug Power
Plug Power Inc has signed a deal with Amazon.com Inc to supply liquid green hydrogen, the companies said on Thursday, sending the hydrogen fuel cell maker's shares up over 12% in early trade.
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.
MindMed Board of Directors Approves Reverse Share Split
Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.
Gold to be the standout metal for the rest of 2022
Following another 75-basis-point hike from the Federal Reserve, gold looks to be the standout metal in the second half of the year.
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.
Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS
Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.
Pasithea Therapeutics Awarded a Drug Development Research Grant
Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.